Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04225-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Elif Baris und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Faculty of Medicine, Izmir University of Economics, Sakarya Cd. 156, 35330, Izmir, Türkiye. elif.baris@ieu.edu.tr. Hauptthemen laut MEDLINE: alpha7 Nicotinic Acetylcholine Receptor, Anti-Inflammatory Agents, Liraglutide, Inflammation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Izmir University of Economics.
Abstract (Originalsprache)
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is well-established for its metabolic benefits, including glycemic control and weight loss. Beyond these roles, it exhibits significant anti-inflammatory properties, though the mechanisms remain underexplored. This study investigates the anti-inflammatory effects of liraglutide in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophages. Results demonstrate that increasing concentrations of liraglutide suppresses LPS-elevated prostaglandin E2 (PGE2), 6-keto prostaglandin F1α (6-keto-PGF 1α , a stable prostacyclin metabolite) and thromboxane A2 (TXA2), similar to that observed with conventional anti-inflammatory agents, ibuprofen and celecoxib. Mechanistic exploration reveals that liraglutide's anti-inflammatory action is dually-modulated by cyclooxygenase (COX) and nicotinic acetylcholine receptor (nAChR) signaling. The application of non-selective, non-competitive nAChR antagonist or selective and potent α7-nAChR antagonist, mecamylamine (MEC) and methyllycaconitine (MLA), respectively, highlights the involvement of cholinergic pathways in liraglutide's activity. Based on in silico molecular docking analyses, liraglutide exhibits favorable binding affinities to COX-1, COX-2, prostacyclin synthase (PGIS), and α7nAChRs, supporting its potential multi-target anti-inflammatory effects. These findings suggest that the therapeutic potential of liraglutide may go beyond metabolic regulation and may be promising for conditions in which metabolic and inflammatory pathways converge, including inflammation and modulation of cholinergic signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pharmacology, Faculty of Medicine, Izmir University of Economics, Sakarya Cd. 156, 35330, Izmir, Türkiye. elif.baris@ieu.edu.tr.
- Department of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Izmir, Türkiye.
- Department of Medical Pharmacology, Faculty of Medicine, Izmir University of Economics, Sakarya Cd. 156, 35330, Izmir, Türkiye.
Förderung
- Izmir University of Economics
Zitieren
APA
Baris, E., Portakal, H. S., Aslan, A., Firtina Karagonlar, Z., & Tosun, M. (2025). Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04225-5
Vancouver
Baris E, Portakal HS, Aslan A, Firtina Karagonlar Z, Tosun M. Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04225-5
BibTeX
@article{Baris2025,
author = {Baris, Elif and Portakal, Huseyin Saygin and Aslan, Arda and Firtina Karagonlar, Zeynep and Tosun, Metiner},
title = {Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04225-5}
}
EUVIMED